Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
First Claim
Patent Images
1. A peptide inhibitor of an interleukin-23 receptor, or a pharmaceutically acceptable salt thereof, comprising an amino acid sequence consisting of Formula (Xa):
-
X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-X16-X17-X18-X19-X20
(Xa),or a pharmaceutically acceptable salt thereof,whereinX1 is any amino acid or absent;
X2 is any amino acid or absent;
X3 is any amino acid or absent;
X4 is Abu;
X5 is Gln;
X6 is Thr;
X7 is Trp;
X8 is Gln;
X9 is Cys;
X10 is Phe, Tyr, a Phe analog, or a Tyr analog;
X11 is 1-Nal, 2-Nal, Phe(3,4-dimethoxy), or Phe(3,4-Cl2);
X12 is α
-Me-Lys, α
-Me-Leu, α
-Me-Ser, α
-Me-Val, Achc, Acvc, Acpc, Acbc, Aib, or 4-amino-4-carboxy-tetrahydropyran;
X13 is any amino acid;
X14 is any amino acid;
X15 is any amino acid,X16 is any amino acid or absent;
X17 is any amino acid or absent;
X18 is any amino acid or absent;
X19 is any amino acid or absent; and
X20 is any amino acid or absent,wherein the peptide inhibitor is cyclized via a thioether bond between X4 and X9, andwherein 1-Nal is L-1-napthylalanine, 2-Nal is L-2-napthylalanine, Abu is 2-aminobutyric acid, α
-Me-Lys is alpha-methyl-L-Lysine, α
-Me-Leu is alpha-methyl-L-Leucine, α
-Me-Ser is alpha-methyl-L-Serine, α
-Me-Val is alpha-methyl-L-Valine, Ache is 1-aminocyclohexanecarboxylic acid, Acvc is 1-aminocyclopentanecarboxylic acid, Acpc is 1-aminocyclopropylcarboxylic acid, Acbc is 1-aminocyclobutanecarboxylic acid, and Aib is 2-aminoisobutyric acid.
1 Assignment
0 Petitions
Accused Products
Abstract
Peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease, are disclosed.
89 Citations
26 Claims
-
1. A peptide inhibitor of an interleukin-23 receptor, or a pharmaceutically acceptable salt thereof, comprising an amino acid sequence consisting of Formula (Xa):
-
X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-X16-X17-X18-X19-X20
(Xa),or a pharmaceutically acceptable salt thereof, wherein X1 is any amino acid or absent; X2 is any amino acid or absent; X3 is any amino acid or absent; X4 is Abu; X5 is Gln; X6 is Thr; X7 is Trp; X8 is Gln; X9 is Cys; X10 is Phe, Tyr, a Phe analog, or a Tyr analog; X11 is 1-Nal, 2-Nal, Phe(3,4-dimethoxy), or Phe(3,4-Cl2); X12 is α
-Me-Lys, α
-Me-Leu, α
-Me-Ser, α
-Me-Val, Achc, Acvc, Acpc, Acbc, Aib, or 4-amino-4-carboxy-tetrahydropyran;X13 is any amino acid; X14 is any amino acid; X15 is any amino acid, X16 is any amino acid or absent; X17 is any amino acid or absent; X18 is any amino acid or absent; X19 is any amino acid or absent; and X20 is any amino acid or absent, wherein the peptide inhibitor is cyclized via a thioether bond between X4 and X9, and wherein 1-Nal is L-1-napthylalanine, 2-Nal is L-2-napthylalanine, Abu is 2-aminobutyric acid, α
-Me-Lys is alpha-methyl-L-Lysine, α
-Me-Leu is alpha-methyl-L-Leucine, α
-Me-Ser is alpha-methyl-L-Serine, α
-Me-Val is alpha-methyl-L-Valine, Ache is 1-aminocyclohexanecarboxylic acid, Acvc is 1-aminocyclopentanecarboxylic acid, Acpc is 1-aminocyclopropylcarboxylic acid, Acbc is 1-aminocyclobutanecarboxylic acid, and Aib is 2-aminoisobutyric acid. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)
-
Specification